TY - JOUR
T1 - HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment
AU - Milde, Till
AU - Lodrini, Marco
AU - Savelyeva, Larissa
AU - Korshunov, Andrey
AU - Kool, Marcel
AU - Brueckner, Lena M.
AU - Antunes, André S.L.M.
AU - Oehme, Ina
AU - Pekrun, Arnulf
AU - Pfister, Stefan M.
AU - Kulozik, Andreas E.
AU - Witt, Olaf
AU - Deubzer, Hedwig E.
N1 - Funding Information:
Acknowledgments We thank Jasmin Wünschel, Markus Sohn, Christina Xanthopoulos, Diana Rieker, Peter van Sluis, and Richard Volckmann for excellent technical assistance. Work was supported by a grant from the University of Heidelberg through the OLYMPIA MORATA program to H.E.D., and a grant from the Interdisciplinary Research Program (NCT-IFP) of the National Center of Tumor Diseases, Heidelberg, Germany, to T.M. and S.M.P. The experiments comply with the current laws of the country in which they were performed. The authors declare that they have no conflict of interest.
PY - 2012/12
Y1 - 2012/12
N2 - Medulloblastomas are the most common malignant brain tumors in childhood. Emerging evidence suggests that medulloblastoma comprises at least four distinct diseases (WNT, SHH, Group 3 and 4) with different biology, clinical presentation, and outcome, with especially poor prognosis in Group 3. The tight connection of biology and clinical behavior in patients emphasizes the need for subgroup-specific preclinical models in order to develop treatments tailored to each subgroup. Herein we report on the novel cell line HD-MB03, isolated from tumor material of a patient with metastasized Group 3 medulloblastoma, and preclinical testing of different histone deacetylase inhibitors (HDACis) in this model. HD-MB03 cells grow long term in vitro and form metastatic tumors in vivo upon orthotopic transplantation. HD-MB03 cells reflect the original Group 3 medulloblastoma at the histological and molecular level, showing large cell morphology, similar expression patterns for markers Ki67, p53, and glial fibrillary acidic protein (GFAP), a gene expression profile most closely matching Group 3 medulloblastomas, and persistence of typical molecular alterations, i.e., isochromosome 17q [i(17q)] and MYC amplification. Protein expression analysis of HDACs 2, 5, 8, and 9 as well as the predictive marker HR23B showed intermediate to strong expression, suggesting sensitivity to HDACis. Indeed, treatment with HDACis Helminthosporium carbonum (HC)-toxin, vorinostat, and panobinostat revealed high sensitivity to this novel drug class, as well as a radiation-sensitizing effect with significantly increased cell death upon concomitant treatment. In summary, our data indicate that HD-MB03 is a suitable preclinical model for Group 3 medulloblastoma, and HDACis could represent a therapeutic option for this subgroup.
AB - Medulloblastomas are the most common malignant brain tumors in childhood. Emerging evidence suggests that medulloblastoma comprises at least four distinct diseases (WNT, SHH, Group 3 and 4) with different biology, clinical presentation, and outcome, with especially poor prognosis in Group 3. The tight connection of biology and clinical behavior in patients emphasizes the need for subgroup-specific preclinical models in order to develop treatments tailored to each subgroup. Herein we report on the novel cell line HD-MB03, isolated from tumor material of a patient with metastasized Group 3 medulloblastoma, and preclinical testing of different histone deacetylase inhibitors (HDACis) in this model. HD-MB03 cells grow long term in vitro and form metastatic tumors in vivo upon orthotopic transplantation. HD-MB03 cells reflect the original Group 3 medulloblastoma at the histological and molecular level, showing large cell morphology, similar expression patterns for markers Ki67, p53, and glial fibrillary acidic protein (GFAP), a gene expression profile most closely matching Group 3 medulloblastomas, and persistence of typical molecular alterations, i.e., isochromosome 17q [i(17q)] and MYC amplification. Protein expression analysis of HDACs 2, 5, 8, and 9 as well as the predictive marker HR23B showed intermediate to strong expression, suggesting sensitivity to HDACis. Indeed, treatment with HDACis Helminthosporium carbonum (HC)-toxin, vorinostat, and panobinostat revealed high sensitivity to this novel drug class, as well as a radiation-sensitizing effect with significantly increased cell death upon concomitant treatment. In summary, our data indicate that HD-MB03 is a suitable preclinical model for Group 3 medulloblastoma, and HDACis could represent a therapeutic option for this subgroup.
KW - Group 3
KW - HC-toxin
KW - Irradiation
KW - Medulloblastoma
KW - MYC
KW - Panobinostat
KW - Vorinostat
UR - http://www.scopus.com/inward/record.url?scp=84871275799&partnerID=8YFLogxK
U2 - 10.1007/s11060-012-0978-1
DO - 10.1007/s11060-012-0978-1
M3 - Article
C2 - 23054560
AN - SCOPUS:84871275799
SN - 0167-594X
VL - 110
SP - 335
EP - 348
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
IS - 3
ER -